Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

214.66 +0.66 (+0.31%)
Streaming Delayed Price Updated: 11:47 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Resmed Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Electronic Arts, TD SYNNEX And 2 Other Stocks Insiders Are Selling
The Nasdaq index closed lower on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
ResMed Earnings Perspective: Return On Capital Employed
Via Benzinga
What's Going On With ResMed Stock Today
ResMed Inc (NYSE: RMD) posted Q3 profits of $247.8 million, with adjusted EPS of $1.68, up from $1.32 a year ago, beating the consensus of $1.59. Revenues increased 29% to $1.12 billion, as continued... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
3 Incredible Growth Stocks to Buy Right Now
These mid-cap growth stocks could deliver market-beating returns in 2023 and beyond. 
Via The Motley Fool
$100 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Hopeful Golden Cross Forms On ResMed's Chart
Via Benzinga
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,300 Today
Via Benzinga
Expert Ratings for ResMed
Via Benzinga
$1000 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Earnings Scheduled For January 26, 2023
Companies Reporting Before The Bell • Nokia (NYSE:NOK) is estimated to report quarterly earnings at $0.14 per share on revenue of $7.20 billion. 
Via Benzinga
A Preview Of ResMed's Earnings
Via Benzinga
Looking Into ResMed's Return On Capital Employed
According to Benzinga Pro, during Q1, ResMed (NYSE:RMD) earned $210.48 million, a 7.9% increase from the preceding quarter. ResMed also posted a total of $950.29 million in sales, a 3.89% increase... 
Via Benzinga
Company Report Roundup: Tesla, Tractor Supply, American Express, and More
Plus a look at investing books, stocks to watch, and other topics for investors. 
Via The Motley Fool
Silk Road Medical Stock Scores Relative Strength Rating Upgrade
Silk Road Medical sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
Competitor Recall Continues To Show Opportunities For ResMed
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
Where ResMed Stands With Analysts
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Hopeful Golden Cross Forms On ResMed's Chart
If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE:RMD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. 
Via Benzinga
Tuesday Is Your Last Chance To Buy ResMed Before The Dividend Payout
  Tuesday marks the last chance for investors to receive the next dividend payout from ResMed (NYSE:RMD). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $3,400 Today
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.43% on an annualized basis producing an average annual return of 19.33%. Currently, ResMed has a market capitalization of... 
Via Benzinga
How Is The Market Feeling About ResMed?
ResMed's (NYSE:RMD) short percent of float has fallen 6.8% since its last report. The company recently reported that it has 1.39 million shares sold short, which is 0.96% of all... 
Via Benzinga
Semiconductor Shortages - See How ResMed Is Tackling
ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips.  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.